Heartflow (NASDAQ:HTFL – Get Free Report) had its price target hoisted by Canaccord Genuity Group from $45.00 to $56.00 in a research report issued on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective suggests a potential upside of 11.27% from the company’s current price.
A number of other equities research analysts also recently commented on HTFL. Stifel Nicolaus lifted their target price on Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Benchmark reiterated a “buy” rating on shares of Heartflow in a research report on Friday, August 14th. Freedom Capital raised shares of Heartflow to a “strong-buy” rating in a research report on Tuesday, June 30th. Wells Fargo & Company upped their price target on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research note on Friday, August 14th. Finally, UBS Group started coverage on Heartflow in a research report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.25.
Get Our Latest Stock Report on HTFL
Heartflow Trading Down 0.8%
Heartflow (NASDAQ:HTFL – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business had revenue of $64.08 million during the quarter. Heartflow’s revenue for the quarter was up 47.7% on a year-over-year basis. As a group, equities research analysts predict that Heartflow will post -0.75 EPS for the current year.
Insiders Place Their Bets
In other news, insider Campbell Rogers sold 19,682 shares of the company’s stock in a transaction on Friday, September 18th. The stock was sold at an average price of $50.15, for a total transaction of $987,052.30. Following the sale, the insider owned 79,956 shares of the company’s stock, valued at approximately $4,009,793.40. This represents a 19.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Vikram Verghese sold 16,766 shares of the stock in a transaction on Friday, September 18th. The shares were sold at an average price of $50.75, for a total value of $850,874.50. Following the completion of the sale, the chief financial officer owned 155,183 shares in the company, valued at approximately $7,875,537.25. The trade was a 9.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 326,667 shares of company stock worth $14,233,123 in the last ninety days. 7.70% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Heartflow
Hedge funds have recently bought and sold shares of the stock. Integrated Wealth Concepts LLC acquired a new position in shares of Heartflow during the second quarter worth about $53,000. Essential Partners LLC acquired a new stake in Heartflow in the first quarter valued at approximately $57,000. Caitong International Asset Management Co. Ltd purchased a new position in Heartflow in the fourth quarter worth approximately $72,000. Strs Ohio grew its holdings in Heartflow by 35.3% during the 1st quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after acquiring an additional 1,200 shares in the last quarter. Finally, Bessemer Group Inc. purchased a new stake in shares of Heartflow in the 1st quarter valued at approximately $126,000.
About Heartflow
Heartflow, Inc is a medical technology company that develops artificial intelligence and imaging solutions for the diagnosis and management of coronary artery disease. Its platform analyzes data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries.
The company’s primary offering, Heartflow Analysis, is designed to provide noninvasive estimates of fractional flow reserve derived from computed tomography (FFRCT).
Read More
- Five stocks we like better than Heartflow
- Nucor and Steel Dynamics Just Pulled Back—The Steel Story Still Looks Strong
- Amazon’s $8 Billion Generac Deal Shows AI’s New Power Bottleneck
- Can Bloom Energy Pop the Top Off AI’s Massive Energy Bottleneck?
- Coach’s Momentum Powers Tapestry Despite the Stock’s Sharp Pullback
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
